[ad_1] For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the…
[ad_1] An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month,…
[ad_1] Analysts are largely optimistic about a new class of anti-obesity medications following a landmark study released over the weekend. Novo Nordisk ‘s Select study of about 17,500 people found the use of its Wegovy decreased the risk of serious cardiovascular complications such as heart attacks. The study, which was shared at the American Heart…
[ad_1] More than 40% of adults in the U.S. are obese. That’s a big number, which makes the group a force to be reckoned with if their habits start to change suddenly. That’s why we’ve seen so many Wall Street analysts exploring the potential fallout from new weight loss medications like Novo Nordisk’s Wegovy and…
[ad_1] As new weight loss medications garnered buzz last year, analysts’ forecasts signaled these drugs would be blockbusters, with some of the highest estimates calling for peak sales of at least $100 billion. In recent days, the expectations are moving higher still. The initial projections were made before Wall Street saw the results of Novo…
[ad_1] Industry analysts are insisting that new weight loss and diabetes drugs like Ozempic won’t hurt the demand for insulin pumps and continuous glucose monitors, but most investors aren’t buying it. Medical device stocks have been falling session after session, prompting UBS analyst Danielle Antalffy on Wednesday to lower her price targets for Dexcom and…
